Monthly Cost Breakdown: Wegovy vs Mounjaro UK Pricing
Wegovy or Mounjaro UK: Understanding Monthly Treatment Costs
When comparing Wegovy or Mounjaro UK options, monthly costs vary significantly based on dose escalation schedules and maintenance requirements. Wegovy follows a structured 16-week escalation from £79.99 monthly (0.25mg starter dose) to £209.99 monthly (2.4mg maintenance dose). Mounjaro uses a different tirzepatide-based approach with its own pricing structure and dose progression. Both prescription-only medicines require ongoing monthly investment, making cost transparency essential for treatment planning.
The key difference lies in the escalation timeline and maintenance costs. Wegovy's semaglutide formula reaches maintenance dosing at week 17, whilst Mounjaro's dual GIP/GLP-1 mechanism follows alternative scheduling. EverydayMeds provides detailed monthly cost calculators for both Wegovy or Mounjaro UK treatments, ensuring patients understand their financial commitment before starting either therapy. Our clinical team helps determine which option aligns with both medical needs and budget considerations.
Detailed Wegovy Monthly Pricing Structure
Wegovy monthly costs progress through five distinct phases during the MHRA-approved dose escalation. Month 1 begins at £79.99 for the 0.25mg starter dose, increasing to £94.99 monthly for the 0.5mg dose (weeks 5-8). The progression continues to £99.99 monthly for 1mg dosing (weeks 9-12), then £139.99 monthly for 1.7mg dosing (weeks 13-16). Finally, maintenance dosing at 2.4mg costs £209.99 monthly from week 17 onwards, representing your long-term investment in weight management.
Our bundle options help manage these escalating costs more effectively. The Intro Trio (0.25mg, 0.5mg, and 1mg) provides three months of escalation dosing for £299.99, whilst the Ultimate Stability Trio offers three months of maintenance 2.4mg dosing for £649.99. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to maintain competitive pricing throughout their Wegovy or Mounjaro UK treatment journey.
Clinical Evidence Supporting Wegovy or Mounjaro UK Investment
The STEP clinical trials demonstrate why Wegovy's monthly cost represents value for weight management investment. In the pivotal STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 5 extension showed sustained clinically studied weight loss at two years, supporting long-term monthly cost commitment.
Recent SELECT cardiovascular outcomes data revealed Wegovy may reduce major cardiovascular events by 20% in eligible patients. This additional health benefit context helps justify the monthly investment when comparing Wegovy or Mounjaro UK options. Both treatments require ongoing commitment, but clinical evidence supports the potential health returns on monthly treatment costs over time.
How Wegovy Works to Justify Monthly Investment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones produced in your intestine. This mechanism reduces appetite and promotes satiety after smaller meals, helping create the caloric deficit necessary for weight management. The treatment works on brain appetite centres, potentially reducing food cravings and emotional eating patterns. Unlike simple appetite suppressants, Wegovy's action supports sustainable eating behaviour changes. These physiological effects justify the monthly cost by providing genuine metabolic support rather than temporary hunger suppression.
Streamlined Ordering Process for Wegovy or Mounjaro UK
EverydayMeds simplifies accessing either Wegovy or Mounjaro UK through our efficient online process. Complete our 3-minute clinical assessment covering medical history, current medications, and weight management goals. Our prescribers review applications within 3 working days (express 24-hour option available), ensuring appropriate treatment selection. Once approved, we dispatch your prescription-only medicine via next-day cold-chain delivery, maintaining the 2-8°C storage requirements. This streamlined process minimises delays between prescription approval and treatment commencement, helping you start your monthly dosing schedule promptly.
Storage Advantages: Wegovy vs Mounjaro UK Practical Considerations
Wegovy offers superior storage flexibility compared to Mounjaro, providing 6 weeks room temperature stability versus Mounjaro's 21-day limit. Store unopened Wegovy pens at 2-8°C in your fridge, but once removed, they remain stable at room temperature (below 30°C) for up to 6 weeks. The FlexTouch pen system ensures accurate dosing throughout the escalation schedule, from 0.25mg starter doses through 2.4mg maintenance. This extended room temperature stability makes Wegovy particularly suitable for frequent travelers or those with refrigeration concerns. The practical storage advantage adds value to your monthly investment when comparing Wegovy or Mounjaro UK options.
Annual Cost Planning for Wegovy or Mounjaro UK Treatment
Effective budgeting requires understanding annual costs beyond monthly payments when choosing Wegovy or Mounjaro UK. Wegovy's first year costs approximately £2,089 including the 16-week escalation period and 36 weeks of maintenance dosing. Subsequent years cost £2,520 annually for continuous 2.4mg maintenance dosing. These calculations assume consistent monthly supply without treatment breaks or dose adjustments.
Budget-conscious patients can utilise our bundle options to manage cash flow more effectively. The Ultimate Stability Trio provides quarterly 2.4mg supply for £649.99, reducing order frequency whilst ensuring treatment continuity. Consider setting aside £210 monthly once reaching maintenance dosing to prepare for ongoing Wegovy or Mounjaro UK costs. This forward planning approach helps maintain treatment consistency despite the significant monthly investment required.
Securing Your Wegovy Supply with Confidence
Start your Wegovy or Mounjaro UK comparison by exploring our transparent pricing at https://everydaymeds.co.uk/collections/wegovy. New customers receive immediate savings with code FIRST40, whilst our DOSE25 code ensures returning patients maintain competitive monthly costs throughout treatment. Our GPhC-registered pharmacy (#9012878) ensures genuine Novo Nordisk Wegovy with full temperature-controlled logistics. Complete your clinical assessment today to begin the prescriber review process. Remember, both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns with your medical needs and monthly budget requirements.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
